Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 12—December 2008

Clinical Characteristics and Molecular Subtyping of Vibrio vulnificus Illnesses, Israel

Ronit Zaidenstein, Chantal Sadik, Larisa Lerner, Lea Valinsky, June Kopelowitz, Ruth Yishai, Vered Agmon, Michele B. Parsons, Cheryl Bopp, and Miriam WeinbergerComments to Author 
Author affiliations: Assaf Harofeh Medical Center, Zerifin, Israel (R. Zaidenstein, M. Weinberger); Israel Ministry of Health, Jerusalem, Israel (C. Sadik, L. Lerner, L. Valinsky, J. Kopelowitz, R. Yishai, V. Agmon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Parsons, C. Bopp); Tel Aviv University, Ramat Aviv, Israel (M. Weinberger)

Main Article

Table 2

Variables associated with death in laboratory-confirmed Vibrio vulnificus infection, by univariable analysis, Israel, 1998–2005*

Clinical characteristics Alive,† n = 84 Dead,† n = 10 p value
Mean age ± SD, y 62.3 ± 18.2 69.2 ± 15.8 NS
Female, no. (%) 60 (49.2) 8 (80) NS
Septic shock, no. (%) 41 (4.9)† 6 (60) <0.001
Bacteremia, no. (%) 24 (28.6) 7 (70) 0.013
Ischemic heart disease, no. (%) 4 (4.8) 4 (40) 0.004
Altered immune status,‡ no. (%) 6 (7.1) 3 (30) 0.052

*NS, not significant.
†n = 81.
‡Due to malignancy or immunosuppressive state.

Main Article

Page created: July 22, 2010
Page updated: July 22, 2010
Page reviewed: July 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.